The Great Biotech Reset | Ep. 645
Down Rounds, Secondary Sales, and the Future of Startup Liquidity
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary is as always on Thursday focused on the general market update. For the week XBI was UP +6% and remains red at -16% for the year. Today's newsletter will cover the mounting liquidity crunch facing venture-backed startups and why biotech isn’t exempt. With venture funding still …
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.